Novartis Culls Pipeline As ‘Pure-Play’ Drive Progresses

Removes PD-1 Inhibitor, Adds To Radioligand Pipeline

 
• By Andrew McConaghie
  
Novartis NIBR Cambridge, MA

More from Earnings

More from Business